Consensus EPS · Q3 2026
$2.94
Consensus revenue · Q3 2026
$1.7B
Analysts
10
Expected report
Oct 21, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 10 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $1.6B | $1.7B | $1.8B |
| EPS | $2.81 | $2.94 | $3.15 |
| EBITDA | $1.5B | $1.5B | $1.6B |
| EBIT | $1.5B | $1.5B | $1.5B |
| Net income | $1B | $1.1B | $1.1B |
- Revenue$1.7B
- EPS$2.94
- EBITDA$1.5B
- EBIT$1.5B
- Net income$1.1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $1.7B | $1.7B | +1.4% | $2.99 | $2.91 | +2.9% |
| Q1 2026 | $1.9B | $1.9B | +0.3% | $3.36 | $3.34 | +0.5% |
| Q4 2025 | $1.7B | $1.6B | +0.2% | $2.77 | $2.75 | +0.7% |
- Q2 2026+1.4%+2.9%
- Q1 2026+0.3%+0.5%
- Q4 2025+0.2%+0.7%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for CME Group (CME) Q3 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 4 analysts.
- Low
- $260.00
- Consensus
- $304.33
- Median
- $309.00
- High
- $330.00
- Current
- $255.31
- Upside
- +19.2%
Upside calculated vs most recent trading price of $255.31.
Analyst ratings
Consensus: Hold — based on 37 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 23, 2026 | JP Morgan | maintain | Underweight | Underweight |
| Jul 23, 2026 | B of A Securities | maintain | Underperform | Underperform |
| Jul 15, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| Jul 10, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 9, 2026 | Barclays | maintain | Equal Weight | Equal Weight |
| Jul 8, 2026 | TD Cowen | maintain | Buy | Buy |
| Jul 6, 2026 | UBS | maintain | Neutral | Neutral |
| Jul 2, 2026 | Raymond James | maintain | Outperform | Outperform |
| Jun 22, 2026 | TD Cowen | maintain | Buy | Buy |
- Jul 23, 2026Morgan StanleyOverweight
- Jul 23, 2026JP MorganUnderweight
- Jul 23, 2026B of A SecuritiesUnderperform
- Jul 15, 2026Piper SandlerOverweight
- Jul 10, 2026Morgan StanleyOverweight
- Jul 9, 2026BarclaysEqual Weight
- Jul 8, 2026TD CowenBuy
- Jul 6, 2026UBSNeutral
- Jul 2, 2026Raymond JamesOutperform
- Jun 22, 2026TD CowenBuy
Frequently asked questions
CME Group (CME) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.03% TTM
- Dividend Profile4.41% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History1 split
How this company returns cash to shareholders — buybacks, dividends, and stock splits.